Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1953 1
1956 1
1958 2
1959 1
1960 1
1967 1
1969 4
1971 1
1972 2
1975 1
1978 2
1979 1
1980 1
1982 1
1987 1
1989 2
1990 1
1992 2
1993 1
1994 1
1997 2
1999 1
2001 3
2003 6
2004 2
2005 2
2007 3
2008 2
2009 3
2010 1
2011 2
2012 1
2013 3
2014 1
2016 1
2017 2
2018 1
2019 1
2021 2
2022 1
2023 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Level frequency postulate and the dice analog.
Mace JL, Peery TB, Teare SW. Mace JL, et al. Among authors: peery tb. Phys Rev E. 2023 Nov;108(5-1):054120. doi: 10.1103/PhysRevE.108.054120. Phys Rev E. 2023. PMID: 38115435
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Aug 13;11(1):241. doi: 10.1038/s41531-025-01103-y. NPJ Parkinsons Dis. 2025. PMID: 40804248 Free PMC article. No abstract available.
Incidence and Effects of Feeding Intolerance in Trauma Patients.
Virani FR, Peery T, Rivas O, Tomasek J, Huerta R, Wade CE, Lee J, Holcomb JB, Uray K. Virani FR, et al. Among authors: peery t. JPEN J Parenter Enteral Nutr. 2019 Aug;43(6):742-749. doi: 10.1002/jpen.1469. Epub 2018 Dec 3. JPEN J Parenter Enteral Nutr. 2019. PMID: 30508254
Kluver-Bucy syndrome related to glioma.
Badruddoja MA, Vredenburgh J, Peery TS, Reardon DA. Badruddoja MA, et al. Among authors: peery ts. Neurology. 2004 Jul 13;63(1):184. doi: 10.1212/01.wnl.0000132961.60435.b7. Neurology. 2004. PMID: 15249638 No abstract available.
Horizons in pathology.
PEERY TM. PEERY TM. J Am Med Assoc. 1959 Dec 12;171:2065-8. doi: 10.1001/jama.1959.03010330027008. J Am Med Assoc. 1959. PMID: 14431372 No abstract available.
68 results